Incyte Corporation Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Incyte Corporation's estimated annual revenue is currently $2.9B per year.(i)
  • Incyte Corporation's estimated revenue per employee is $1,208,472
  • Incyte Corporation's total funding is $3.5M.
  • Incyte Corporation's current valuation is $16.5B. (January 2022)

Employee Data

  • Incyte Corporation has 2408 Employees.(i)
  • Incyte Corporation grew their employee count by 15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Incyte\'s vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have an experienced management and discovery team. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in healthcare, improve the lives of patients and build significant sustainable value for our shareholders.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Incyte Corporation News

2022-04-20 - 2022-04-28 | NDAQ:INCY | Press Release | Incyte Corporation

Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan. INCY | 6 hours ago. Incyte (NASDAQ:INCY) and Maruho Co.,...

2022-04-19 - Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

Incyte Corporation INCY is scheduled to release first-quarter 2022 results on May 3, before the market opens. The company's earnings...

2022-04-13 - Is Incyte Corporation (INCY) Stock a Smart Value?

Incyte Corporation (INCY) stock is down -8.42% over the last 12 months, and the average rating from Wall Street analysts is a Buy.

2021-09-30 - Incyte : OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata

INDIANAPOLIS, Sept. 30, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily OLUMIANT® (baricitinib) 4-mg was superior to placebo in achieving significan ...

2021-07-28 - Incyte : Announces Progress on Global Responsibility Initiatives and Sets Corporate Goals for the Next Four Years

∙ ∙ ∙ ∙ 2 Attachments Original document Permalink Disclaimer Incyte Corporation published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2021 18:33:05 UTC.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding